

References

I-200

1. Aimovig (erenumab-aooe) injection for subcutaneous use [package insert]. Amgen Inc. Thousand Oaks, CA. Revised 03/2019.
2. Ajovy (fremanezumab-vfrm) injection for subcutaneous use [package insert]. Teva Pharmaceuticals. North Wales, PA. Revised 01/2019.
3. Emgality (galcanezumab-gnlm) injection for subcutaneous use [package insert]. Eli Lilly and Co. Indianapolis, IN. Revised 10/2018.
4. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. *Cephalalgia*. 2018;38(I):1-211.
5. Draft Evidence Report: Calcitonin Gene-Related Peptide (CGRP) Inhibitors as preventive treatments for patients with episodic or chronic migraine: effectiveness and value. ICER- Institute for Clinical and Economic Review. April 11, 2018.
6. Bigal ME, Dodick DW, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. *Lancet Neurol*. 2015;14(11):1081-1090.
7. Bigal ME, Edvinsson L, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. *Lancet Neurol*. 2015;14(11):1091-1100.
8. Tepper, S, Ashina, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. *Lancet Neurology*. 2017;16(6):425-434.
9. Goadsby, P J, Reuter, et al. A controlled trial of erenumab for episodic migraine. *New England Journal of Medicine*. 2017;377(22):2123-2132.
10. Micromedex®Solutions Compendia. 2019. Erenumab-aooe.
11. Micromedex®Solutions Compendia. 2019. Fremanezumab-vfrm.
12. Micromedex®Solutions Compendia. 2019. Galcanezumab-gnlm.
13. Clinical Pharmacology Compendia [database online]. Tampa FL: Gold Standard, Inc. Erenumab-aooe. 2019.
14. Clinical Pharmacology Compendia [database online]. Tampa FL: Gold Standard, Inc. Fremanezumab-vfrm. 2019.
15. Clinical Pharmacology Compendia [database online]. Tampa FL: Gold Standard, Inc. Galcanezumab-gnlm. 2019.